FDA staff raises efficacy doubts on GSK's lung disease treatment

Submitted by admin on July 23, 2018 - 9:38am

Source:

Yahoo/Reuters

News Tags:

GSK

FDA

Nucala

COPD

Headline:

FDA staff raises efficacy doubts on GSK's lung disease treatment

snippet:

U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs.

Search form

You are here

FDA staff raises efficacy doubts on GSK's lung disease treatment

FDA staff raises efficacy doubts on GSK's lung disease treatment